Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

4,577JPY
17 Jul 2018
Change (% chg)

¥97 (+2.17%)
Prev Close
¥4,480
Open
¥4,463
Day's High
¥4,595
Day's Low
¥4,447
Volume
2,377,200
Avg. Vol
2,023,526
52-wk High
¥4,595
52-wk Low
¥2,284

Chart for

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.78
Market Cap(Mil.): ¥3,176,371.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.56

Financials

  4568.T Industry Sector
P/E (TTM): 49.51 29.21 33.15
EPS (TTM): 90.48 -- --
ROI: 3.81 13.66 13.23
ROE: 5.22 15.51 15.27

Nikkei rises in volatile trade helped by China stock gains

TOKYO Japan's Nikkei share average rose in volatile trade on Wednesday, helped by late short-covering following an earlier selloff and a broader recovery in regional sentiment as Chinese shares recovered from a rout in the previous session.

Jun 20 2018

Nikkei rises in volatile trade helped by China stock gains

TOKYO, June 20 Japan's Nikkei share average rose in volatile trade on Wednesday, helped by late short-covering following an earlier selloff and a broader recovery in regional sentiment as Chinese shares recovered from a rout in the previous session.

Jun 20 2018

Nikkei flat in choppy trade as trade war woes pressures; Kikkoman soars

TOKYO, June 20 Japan's Nikkei share average was flat in choppy trade on Wednesday morning as firms that rely on China demand tumbled on trade war worries, with machine tool makers and shippers posting multi-month lows, which offset gains in defensive stocks.

Jun 19 2018

BRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific Antibodies

* ZYMEWORKS AND DAIICHI SANKYO EXPAND IMMUNO-ONCOLOGY COLLABORATION FOCUSED ON BISPECIFIC ANTIBODIES

May 14 2018

BRIEF-Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit

* Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019

Apr 27 2018

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

Apr 04 2018

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

Mar 22 2018

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

Mar 22 2018

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Medrx signs joint development contract with DAIICHI SANKYO

* Says it signed a joint development contract with DAIICHI SANKYO COMPANY, LIMITED, regarding development candidates using Nano-sized Colloid Transdermal System owned by the company

Feb 28 2018

Earnings vs. Estimates